RTW Biotech Opportunities Fund Inc. reported a July net asset value of $2.82 per share, a decrease from the $2.91 recorded in June, according to a regulatory filing.
The fund, which invests in biotechnology and life sciences companies, disclosed the monthly NAV adjustment in a document filed with the U.S. Securities and Exchange Commission. The decline reflects valuation changes in its underlying portfolio holdings during the month.
RTW Biotech Opportunities, listed on the Nasdaq under the ticker RTW, is a closed-end fund managed by RTW Investments. The fund focuses on equity investments in biotech firms, primarily those engaged in drug development and commercialization.
The July NAV update follows the fund's June 30 valuation, which served as the reference point for the latest calculation. Closed-end funds typically report NAVs monthly to provide transparency on portfolio performance and asset allocation changes.
